Non-invasive neuromodulation of the right temporoparietal junction using theta-burst stimulation in functional neurological disorder

Janine Bühler,1,2 Samantha Weber,1 Serafeim Loukas,1,3 Sebastian Walther,4 Selma Aybek1,5

ABSTRACT

Background Disrupted sense of agency (SoA)—the sense of being the agent of one’s own actions—has been demonstrated in patients with functional neurological disorder (FND), and a key area of the corresponding neuronal network is the right temporoparietal junction (rTPJ). Several functional MRI (fMRI) studies have found hypoactivation as well as hyperactivation of the rTPJ in FND. In a proof-of-concept study, we tested whether repetitive transcranial magnetic stimulation (rTMS) over the rTPJ could restore this aberrant activity.

Methods In a randomised, crossover, single-blinded, sham-controlled study design, theta-burst stimulation (tb-rTMS) was applied over the rTPJ in 23 patients with FND and 19 healthy controls (HC), with each participant undergoing three stimulatory visits (inhibitory continuous TBS (cTBS), excitatory intermittent TBS (iTBS) and sham). During fMRI, participants played a visuomotor task artificially reducing their SoA (manipulated agency, MA), repeated after each neurostimulation. We compared brain activity and behavioural SoA as primary outcomes before and after tb-rTMS and investigated the feasibility of tb-rTMS over the rTPJ in FND as secondary outcome.

Results At baseline, patients showed decreased accuracy in detecting reduced agency compared with controls (p<0.001), paralleled by lower brain activation in the rTPJ during MA (p=0.037, volume of interest). A region of interest analysis on the rTPJ showed no effect of the sham condition in FND or HC (p=0.917; p=0.375) but revealed a significant effect of stimulation protocol (cTBS/iTBS; p=0.037) in patients with FND, with the excitatory protocol increasing the blood-oxygen-level-dependent (BOLD) signal, whereas this effect was not found in HC. In neither group, a behavioural effect of tb-rTMS was observed.

Conclusion Aberrant processing of agency in FND was confirmed at baseline, reflected in behavioural outcome and reduced activity in the rTPJ. Tb-rTMS over this key region elicited neuronal changes in patients, paving the way for future studies exploring TMS as neurobiologically informed intervention to restore SoA in FND. We critically discuss methodological intricacies and outline further steps in this research line.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Functional neurological disorder (FND) has been associated with a disrupted sense of agency (SoA) and an aberrant activity and functional connectivity of the right temporoparietal junction (rTPJ) which delineates a key node in the agency network. Most of the previous studies investigated behaviour and brain activity separately or were limited to methods of correlative nature, while interventional studies aiming to elaborate on the potential to modulate abnormal rTPJ activity in order to restore SoA in FND are lacking.

WHAT THIS STUDY ADDS

⇒ By combining neurostimulation (theta-burst repetitive transcranial magnetic stimulation, tb-rTMS) and task-based neuroimaging (functional MRI), reduced accuracy in detecting low activity was found to be paralleled by decreased blood-oxygen-level-dependent (BOLD) signal in the rTPJ in patients with FND compared with healthy controls. Furthermore, tb-rTMS revealed a neuromodulatory potential on the rTPJ activity during the performance of the task paradigm.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The evidence of a neuromodulatory potential of the rTPJ as main node during cognitive processing of SoA in patients with FND sets the ground for future clinical trials. These data could serve as rationale and methodological precursor to design and conduct power analysis for a study protocol looking at clinical benefits in parallel to this neuromodulatory finding.

INTRODUCTION

Functional neurological disorder (FND) is a frequent disorder characterised by the presentation of a variety of neurological symptoms in the absence of an identifiable underlying neurological disease responsible for those symptoms.1 A key characteristic is the experience of symptoms as being
produced involuntarily, even though there is evidence that the pathways related to voluntary motor control are capable of normal functioning. To explain this discordance between perceived control over the body and observed motor function, recent research has proposed a disrupted sense of agency (SoA)—the feeling of being the agent of one’s own actions and their consequences—in FND.

Several studies reported aberrant encoding of agency attribution in FND using proxies of SoA such as intentional binding, sensory attenuation, movement in virtual reality or a visuomotor task. Accordingly, neurobiological models have put forward a network disturbance as an explanation for impaired SoA. Of particular interest is the right temporoparietal junction (rTPJ) as a multisensory association cortex that evaluates the concordance between the intention of a movement and the sensory feedback resulting from the executed movement. In FND, abnormal activity and functional connectivity (FC) of the rTPJ have been found in resting-state imaging but also in task-based functional MRI (fMRI) during involuntary or externally generated movements and during recall of traumatic events. Due to conflicting findings of hypoactivation or hyperactivation, deciphering the contribution of this region to FND pathophysiology remains challenging.

Non-invasive brain stimulation (NIBS) can facilitate or inhibit cortical excitability and allows to study specific directional effects on behaviour and neurophysiology. Transcranial magnetic stimulation (TMS) is a NIBS technique, generating a magnetic field which induces local electrical pulses in the brain tissue, altering cortical excitability. Novel protocols of repetitive TMS (rTMS) called theta-burst stimulation (TBS; hereafter tb-rTMS) deliver high-frequency triplets and have been proven to elicit longer-lasting effects—intermittent delivery (iTBS) leads to excitation of cortical membranes, while continuous delivery (cTBS) has shown inhibitory effects.

Although an increasing amount of empirical work on NIBS in FND has emerged recently, reports on rTMS protocols are scarce and constraint with heterogeneity in methods and outcome measures. Only two studies investigated the potential of rTMS over the rTPJ: one case report on a single patient and one case series of seven patients with functional seizures reporting improved symptom severity after rTMS over the rTPJ.

Whereas NIBS has predominantly been used to improve symptom severity in FND, we set out to assess the effect on the SoA’s neural correlates. The rTPJ activity was previously found to be enhanced during an incongruence condition of an action-recognition task with manipulated visuomotor feedback in healthy controls (HC), and behavioural measures of SoA were successfully modulated by cTBS applied over this region. Using the same task along with functional neuroimaging, we compared the processing of SoA between patients with FND and HC and investigated the effect and feasibility of tb-rTMS on the rTPJ in a proof-of-concept study. This aims at filling the gap on physiological evidence about a potential neuromodulatory effect of TMS in FND, prior to translating tb-rTMS protocols to clinical outcome measures.

We hypothesised that (1) patients show a reduced sensitivity in detecting an artificial manipulation of their agency and display rTPJ hypoactivation compared with HC. Targeting the rTPJ, we hypothesised that (2) tb-rTMS has a neuromodulatory effect that can be measured as blood-oxygen-level-dependent (BOLD) signal change in the rTPJ and alters participants’ SoA (primary outcomes) while being well tolerated (secondary outcome).

**MATERIALS AND METHODS**

Patients with FND were recruited and measured at the neurology department at the University Hospital of Bern (Inselspital), Switzerland. The diagnosis was confirmed and enrolment performed by a board-certified neurologist based on the presence of positive signs. Eligible symptom types included motor symptoms (abnormal movements and weakness, F44.4), functional seizures (F44.5) and mixed symptoms (F44.7), according to the International Classification of Diseases 10th Edition (ICD-10) nomenclature. Exclusion criteria were as follows: comorbid psychosis, major depression, bipolar affective disorder, epilepsy, alcohol or drug abuse and contraindication to MRI. Age-matched and sex-matched HC were included applying the same exclusion criteria. All participants provided written informed consent. The study was approved by the Ethics Committee of Canton Bern, Switzerland (2017–00997, DRKS00012992), and followed the guidelines of the Declaration of Helsinki.

**Study design**

A randomised, single-blinded, sham-controlled, neuronavigation-guided, crossover study was conducted, including three interventional visits (visits 1–3, figure 1) so that each participant received excitatory and inhibitory neurostimulation over the rTPJ as well as active sham stimulation over the vertex in random order. At each visit, participants performed the agency task during fMRI before and after the tb-rTMS protocol (run 1–6). Participants were unaware of the effects of the three protocols. The visits occurred with a 1-week interval.

**Clinical data**

We assessed mood (Beck’s Depression Inventory and State-Trait Anxiety Inventory) at each visit and patients’ subjective symptom severity (SSS; visual analogue scale, 1–10) before and after each stimulation. Symptom duration was calculated from the onset of symptoms to the date of first visit.

**Agency task and fMRI acquisition**

The behavioural task performed during fMRI was based on Metcalfe and Greene (figure 2) and had already been used to study SoA in HC and patients, including FND.
The game phase contained two conditions: no manipulation of the cursor in non-Turbulence (non-Turb), whereas an artificial decrease of agency was implemented during Turbulence (Turb) by adding random noise (movement of the cursor to the opposite direction as intended or no cursor movement at all) to 25% of the participants’ button clicks. Participants rated judgement of performance (JoP) and judgement of agency (JoA) on a Likert scale from −5 (‘very poor’) to +5 (‘very high’). Each game phase was presented for 15s, whereas the judgements relied on confirmation and thus were self-paced. Details on MRI acquisition are presented in online supplemental material A.

**Transcranial magnetic stimulation**

The three stimulation protocols are exposed in table 1. Details on neuronavigation for target localisation are available in online supplemental material C.

**Analyses**

Analyses of neuroimaging and behaviour (primary outcomes) were divided into baseline and stimulation effect. For baseline, data acquired in runs prior to neurostimulation (1/3/5) were pooled to study group characteristics irrespective of tbrTMS. For the stimulation effect, data acquired in all runs (1–6) were included in the analyses to assess the effect of tbrTMS.
Real performance (RP) was computed as

\[ RP = \frac{\text{Hit targets} - \text{Hit non-targets}}{\text{total number stimuli} \times 12} \]

For JoP and JoA, the median for each condition was calculated.

**fMRI analysis**

SPM12 was used for image processing (https://www.fil.ion.ucl.ac.uk/spm/software/spm12). Preprocessing steps are detailed in online supplemental material D.

At the first level, a general linear model (GLM) for each subject's fMRI data was built containing the regressors for each game phase, each judgement phase and six motion regressors as block design. At the second level, we contrasted all non-target trials to all Turb trials ([non-Turb<Jurb]) to build contrast maps representing manipulated agency (MA). One contrast map representing MA at baseline (runs 1\(\sim\)3/5) was created. Six contrast maps encoding MA in each run (1\(\sim\)6) were built to study the stimulation effect. The judgement phase was not considered in the second level analysis, as the duration of JoP (M=2.04s, SD=0.80) and JoA (M=1.67s, SD=0.63) was below the time of repetition.

**rTPJ: volume of interest, region of interest**

At baseline, a whole brain analysis was conducted as quality check to verify that the task activated the agency network (online supplemental figure 1 and online supplemental table 1 in online supplemental material E). As our main hypothesis focused on the role of the rTPJ, we selected a volume of interest (VOI) approach\(^{21}\) which allows addressing structural and functional intersubject heterogeneity in localisation of rTPJ during tasks targeting the SoA.\(^{30}\) Hence, centred around Montreal Neurological Institute (MNI), a sphere of r=15mm was placed on the contrast map representing MA. Within this sphere and for each subject separately, the coordinates of the peak activation were identified and used as centre coordinates for a sphere of r=10mm (k\(_E\)=515 voxels), which was defined as the final region of interest (ROI) for the analysis and matched the cluster size of preceding studies (k\(_E\)=431).\(^{21}\) To verify comparability of the regions between groups, a permutation test (1000 iterations) on the Euclidian distance between centre coordinates of individual ROI and seed coordinates was computed (\(p=0.308\)). Additional ROI analyses were performed on further brain areas linked to the agency network; see online supplemental material H.

To study the stimulation effect, due to the technical impracticality of VOI (ie, resulting bias towards activity before stimulation), the rTPJ was defined as a sphere of r=10mm centred around MNI.\(^{30}\)

All abovementioned ROI masks were overlayed on the corresponding contrast map. Mean contrast estimates within the ROI were extracted and entered to statistical
analyses. We computed a delta score (Δ) by subtracting contrast estimates of poststimulation from those assessed in prestimulation.

**Statistical analysis**
Analyses were performed using MATLAB R2017b (V.9.3) and R studio (V.1.3.1093). In analyses including between-subject factors only, Pearson’s χ² test or Wilcoxon rank-sum test was used on non-parametric data, while t-tests were applied on parametric data. In ROI analyses at baseline, nuisance regression was performed to correct for covariates of no interest (depression and trait anxiety). Testing the effect of each neurostimulation protocol on SSs, we applied false discovery rate (FDR) with FDR = 0.05 to correct for multiple comparisons.

In analyses including between-subject as well as within-subject variables, linear mixed-effect models were estimated allowing a random subject intercept. If included variables had >2 levels, an analysis of variance was applied to determine if the coefficients defined as fixed effects are equal to 0. Covariates of no interest (depression, trait anxiety and order of stimulation) were added to the models. For ROI analysis of the stimulation effect, the effect of sham stimulation was tested on contrast estimates (paired t-test), and Δvrai was added to the abovementioned covariates of no interest, to exclude an indistinct effect deriving from time variations, environmental factors or placebo. To test veridical TMS-induced effects, the model inclusion was limited to real stimulation (cTBS, iTBS; delta scores) and patients to enhance the understanding of pathophysiological mechanisms while excluding bias due to potential ceiling effects in HC.

To test for associations between behavioural data and BOLD signal, Pearson’s product moment correlation coefficient (PCC) was computed between absolute values (JoA and JoP) and mean contrast estimate within VOI at baseline. Investigating the stimulation effect on that association, PCC between absolute changes (post − pre) or relative changes $(\frac{(post−pre)}{pre})$ (sensitive to ceiling or flooring effects) and change in mean contrast estimate within ROI was computed. In case of significance, association was tested in a GLM to correct for covariates of no interest (depression and trait anxiety).

**RESULTS**
Four patients were excluded due to incidental neurological finding in the MRI (n=1), lack of time (n=2) or without specification of reasons (n=1). Four HC were excluded due to non-applicability of TMS (n=1), lack of time (n=1), side effects of TMS (headache, n=1) or missing data during fMRI acquisition (n=1). The final sample consisted of 23 patients and 19 HC. No significant difference in age ($t(39.69)=1.637$, $p=0.110$) or gender distribution ($\chi^2(1, n=42)=0.019$, $p=0.890$) between FND and HC was found. Demographic and clinical characteristics are reported in table 2.

**SoA and rTPJ activity during MA at baseline**
To test group characteristics before neurostimulation, subjective ratings of JoA and neuroimaging data (MA, contrast [non-Turb<Turb]), from all runs prior to tbr-TMS (1/3/5), were included.

**SoA**
At baseline, we detected a game mode and group interaction ($\beta$=−3.105, $SE$=0.306, $p<0.001$), showing that patients adapted their JoA significantly less compared to HC during Turb versus non-Turb (figure 3). A main effect of game mode was observed with both groups reporting lower JoA during Turb than that of no-Turb ($\beta$=−2.444, $SE$=0.186, $p<0.001$). Moreover, patients reported significantly lower JoA compared with that of HC during non-Turb ($W=93.5, p=0.002$).

Analyses of RP and JoP at baseline are detailed in online supplemental material F-G.

**rTPJ activity during MA**
The whole brain analysis is presented in online supplemental material E.

Mean contrast estimate extracted from individual VOI encoding MA ([non-Turb<Turb]) at baseline was compared between groups and showed a significant difference between FND and HC ($t(40)=1.831, p=0.037$; figure 4), which survived correction for depression and trait anxiety ($t(40)=1.720, p=0.047$).

The analysis of further brain areas linked to the agency network based on the parcellation of the automated anatomical labelling atlas 3 (AAL3) revealed group differences in the right middle frontal and right inferior frontal gyrus (online supplemental table 2).

**LINKING JOA TO RTPJ ACTIVITY**
During MA, JoA was found to be positively correlated with the brain activity in the rTPJ (VOI) at baseline in patients ($r=0.572, p=0.004$; figure 4) but not controls ($r=0.272, p=0.260$). In a GLM corrected for depression and trait anxiety, the rTPJ activity was identified as a significant predictor for JoA during MA ($\beta=0.632, SE=0.201, p=0.005$). This association was not observed in JoP ($r=0.011, p=0.960$).

**NEUROMODULATORY POTENTIAL OF TB-rTMS OVER RTPJ ON SOA**
To test the effect of tb-rTMS, subjective ratings of JoA and neuroimaging data (MA, contrast [non-Turb<Turb]), from all runs (1–6), were included.

**Sense of agency**
The model testing the stimulation effect on JoA confirmed a main effect of group ($F(1, 40.95)=37.942, p<0.001$) and a main effect of timepoint ($F(1, 202.70)=4.136, p=0.043$), indicating lower JoA in patients across all sessions and an increase of JoA due to intervention irrespective of stimulation protocol. Moreover, the model showed a significant interaction of group and timepoint ($F(1, 195.76)=7.777, p=0.006$): HC increased their rating from prestimulation to poststimulation runs to a larger extent compared with
Table 2  Participants’ demographic and clinical characteristics at visit 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall, n=42*</th>
<th>Group</th>
<th>P value†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>FND, n=23*</td>
<td>HC, n=19*</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>27 (64%)</td>
<td>15 (65%)</td>
<td>12 (63%)</td>
</tr>
<tr>
<td>Male</td>
<td>15 (36%)</td>
<td>8 (35%)</td>
<td>7 (37%)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>36.8 (13.5)</td>
<td>39.8 (13.9)</td>
<td>33.2 (12.5)</td>
</tr>
<tr>
<td>Handedness§</td>
<td></td>
<td></td>
<td>&gt;0.9</td>
</tr>
<tr>
<td>Right</td>
<td>39 (93%)</td>
<td>21 (91%)</td>
<td>18 (95%)</td>
</tr>
<tr>
<td>Left</td>
<td>3 (7.1%)</td>
<td>2 (8.7%)</td>
<td>1 (5.3%)</td>
</tr>
<tr>
<td>Symptom type‡</td>
<td></td>
<td>11 weaknesses, 3 seizures,</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>14 gait disorders, 1 dystonia,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>7 tremors, 1 myoclonus</td>
<td></td>
</tr>
<tr>
<td>ICD-10 diagnosis</td>
<td>8 F44.4</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2 F44.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13 F44.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom duration (y)</td>
<td>4.21 (3.57)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Subjective symptom severity (SSS)</td>
<td>3.87 (3.14)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Beck’s Depression Inventory</td>
<td>8.8 (8.6)</td>
<td>2.2 (3.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Trait from State-Trait Anxiety Inventory</td>
<td>37.3 (11.5)</td>
<td>29.9 (11.8)</td>
<td>0.066</td>
</tr>
</tbody>
</table>

*n (%), mean (SD). †Pearson’s χ² test, Welch two-sample t-test, Wilcoxon rank-sum test. ‡Patients can present with more than one symptom type. §Deviating this classification: one patient used left instead of dominant right hand during task due to symptoms. FND, functional neurological disorder; HC, healthy controls; ICD-10, International Classification of Diseases 10th Edition; y, year.

Figure 3  Judgement of agency at baseline (runs 1/3/5): subjective ratings displayed for patients with functional neurological disorder versus healthy controls, divided according to condition (non-Turb versus Turb). Error bars indicating SE. FND, functional neurological disorder; HC, healthy controls; JoA, judgement of agency; non-Turb, non-Turbulence.
patients. No interaction of group, timepoint and stimulation was observed ($F(2, 195.76)=0.304$, $p=0.738$).

No effect of stimulation on RP or JoP was found (online supplemental material F,G).

rTPJ activity during MA
To control for a placebo effect, a two-tailed paired $t$-test on contrast estimate was used to test whether the rTPJ activity changed significantly due to sham stimulation, which was neither the case in patients ($t(22)=-0.106$, $p=0.917$) nor in HC ($t(18)=-0.909$, $p=0.375$). Therefore, we tested a model including real stimulation delta scores in patients only and found a significant effect of stimulation (cTBS and iTBS, $\beta=0.403$, $SE=0.187$, $p=0.037$), which survived correcting for depression, trait anxiety and order of stimulation ($\beta=0.403$, $SE=0.187$, $p=0.037$; figure 5, details in online supplemental table 3). Furthermore, by adding $\Delta_{\text{Vertex}}$ as covariate of no interest, the significant effect of stimulation remained even after accounting for a patient’s indistinct sham response ($\beta=0.403$, $SE=0.186$, $p=0.036$). In HC, this effect was not observed (online supplemental table 4).

Linking JoA to rTPJ activity
The relationship between the change in rTPJ (ROI) activity due to stimulation and the change in JoA in FND was investigated. No association between JoA and brain activity was found (online supplemental material I).

Feasibility
In neither group, a severe adverse event (AE) was encountered, with the number of participants reporting AEs being comparable between groups (online supplemental table 5). Moreover, patients’ ratings of SSS did not significantly change due to cTBS ($V=30$, $p=0.603$), iTBS ($V=32$, $p=0.672$) or sham stimulation ($V=21$, $p=0.079$).

DISCUSSION
The first study in the field of FND, combining fMRI and NIBS targeting the agency network, showed (1) a reduced JoA associated with hypoactivation of the rTPJ in FND compared with HC and (2) neuroimaging-based evidence for a neuromodulator potential of tb-rTMS on the rTPJ in FND.

SoA in FN
The behavioural paradigm successfully captured the well-described distorted agency attribution in patients with FND.\textsuperscript{2,4-7} Not only did patients report lower agency (JoA during non-Turb) than that of controls, they were also less able to acknowledge an external manipulation of their
agency (interaction game mode and group), indicating an impairment in the inference of one’s own intentions, motor commands and the resulting outcome.9 Neuroimaging findings confirmed the key role of the rTPJ during the agency task, in accordance with the previous literature agreeing on the experience of agency as the brain’s default state, while disruption of agency leads to an activation of the agency network.33 An increase of rTPJ activity during reduced agency (MA) was found across both groups, but patients had significantly less activity during MA compared with that of HC, supporting findings of hypoactivation in rTPJ in FND.3 13

An association between rTPJ activation and reported SoA (JoA) was found in patients with FND, suggesting the rTPJ being engaged as a resource for the metacognitive evaluation of explicit agency when a decrease of agency is experienced.35 Notably, the rTPJ involvement was unique to the evaluation of agency (no correlation of rTPJ activity and JoP). HC did not show such an association, which might represent higher sensitivity to distortion detection, thus possibly reflecting a ceiling effect.

In summary, we assume that the rTPJ might serve as neurophysiological correlate to the reported disturbance in SoA and potentially relates to the involuntariness of symptoms in FND.3

Neuromodulatory potential of tb-rTMS over rTPJ in FND

Investigating the stimulation effect on subjective JoA, we did not identify significant changes. In contrast to the pooled data at baseline, a limited number of trials were available to infer this complex effect, and we therefore assume a lack of power rather than a negative result. However, we observed an increase of JoA over time across both groups (effect of timepoint), suggesting a non-specific learning effect, which is more pronounced in HC (interaction group and timepoint). This may be of interest to future studies, implicating that SoA could be amenable to training.

Importantly, this study provides the first preliminary evidence for a neurophysiological modulation of the rTPJ during artificially reduced agency in FND. A significant effect on the BOLD signal was found with excitatory iTBS increasing the signal in the rTPJ and inhibitory cTBS eliciting a decrease. Testing the isolated effect of vertex stimulation (contrast estimates) confirmed the absence of a sham-induced change in the rTPJ, and accounting for $\Delta_{\text{Vertest}}$, as proxy for non-specific, time-varying, repetition-related effects or placebo-associated changes as covariate of no interest, the significant difference of cTBS-elicited and iTBS-elicited modulations persisted in the main model, arguing against an exclusively placebo-based effect.

Figure 5  Neurophysiological modulation of repetitive transcranial magnetic stimulation on the right temporoparietal junction (rTPJ) activity during manipulated agency in patients with functional neurological disorder. Mean delta scores ($\Delta$) extracted from region of interest (rTPJ) in patients including continuous theta-burst stimulation and intermittent theta-burst stimulation. Error bars indicating SD. FND, functional neurological disorder; cTBS, continuous theta-burst stimulation; iTBS, intermittent theta-burst stimulation; MA, manipulated agency; MNI, Montreal Neurological Institute; ROI, region of interest; Turb, Turbulence.
Regarding the lack of transfer from neurophysiological to behavioural modulation, it is conceivable that the rTPJ reflects a correlate of a non-conceptual, implicit feeling of agency based on action monitoring, whereas JoA reflects a metacognitive process of explicit agency claiming an integration of multimodal perception and cognitive sources, thus requiring (pre)frontal areas. Hence, tb-rTMS over the rTPJ potentially altered the feeling of agency, whereas the stimulation of this region alone is not sufficient to alter the interplay of areas involved in the judgement of agency.

Despite the absence of a behavioural effect, our findings on changes in rTPJ activity after tb-rTMS contribute to the scientific debate, by reflecting genuine neurophysiological modulatory processes rather than unspecific placebo effects and can thus add to the advances in inferring on therapeutic applicability.

**Feasibility of tb-rTMS in FND**

We report high feasibility and tolerability of tb-rTMS in patients with FND. The applied experimental intervention neither elicited substantial adverse effect nor a rise in SSS. rTMS over the rTPJ was successfully applied in two studies, and one study applied iTBS in FND targeting a different area. Considering the potential of TBS regarding long-term plasticity changes, the available reports of feasibility in FND provide valuable groundwork for future studies.

**Limitations**

Although the presented sample is relatively large in comparison with other rTMS studies in the field, we acknowledge the sample size of 23 patients and 19 HC as a major limitation. This furthermore prevented us from performing subgroup analyses to determine whether specific symptom types would be more responsive to neuromodulation. An additional limitation constitutes the presence of depressive comorbidity in our patient cohort, which may influence the neuroimaging findings. Nonetheless, the results remained significant after correcting for mood scores, whereas psychiatric medication should be addressed in future studies. Finally, TBS protocols have a limitation in themselves as there is an ongoing debate on the precise neurochemical excitatory/inhibitory processes and observed interindividual and intraindividual variability. We can hypothesise that similar variability is responsible for the negative results we obtained on behavioural scores of agency. Measuring the BOLD signal to assess target engagement strengthens our findings, whereas the variability especially in vertex stimulation calls for more attention in upcoming studies and careful selection of control protocols.

**Outlook**

The reported neuromodulatory potential sets grounds for future studies and clinical trials; however, many challenges need to be tackled to develop a neurobiologically informed treatment in FND, and the next steps entail to verify (1) a behavioural effect on agency and (2) a clinical effect on symptom severity. While the first step could be achieved by adapting the number of trials in the agency task and adjusting the sample size, achieving the second step would require adding objective symptom assessment and quality of life as outcome measures. Since the brain is organised in networks—as also the agency network—other hubs could be amenable to neurostimulation, whereas modulation of connectivity between relevant nodes should be investigated in future studies, given the recent demonstration of FC modulation using iTBS in FND. Moreover, advanced placebo delivery setups (eg, sham coils, spacer and sensory stimulation) and collecting a patient’s hypothesis about received stimulation (active/passive) are advised to provide and verify masking while excluding external modulation. By elaborating on optimal and individualised stimulation intensity and location (eg, peak activation during task of interest) and refining the number of applications (considering a dose-dependent mechanism of rTMS), tb-rTMS efficiency might be enhanced, while also other NIBS techniques (eg, rTMS, transcranial direct current stimulation) could be explored.

Lastly, patient characteristics as an indicator for stimulation efficacy and outcome success require attention in future studies (eg, symptom type, symptom duration and comorbidities). Brain-state dependencies could be used to either evaluate eligibility for treatment (eg, resting-state FC) or to boost the treatment response by priming relevant brain circuits (eg, psychotherapy/physiotherapy, suggestion).

**CONCLUSION**

The current study confirmed impaired SoA in patients with FND, which is associated with a decreased rTPJ activation. Furthermore, as a proof-of-concept report, tb-rTMS over the rTPJ revealed the potential for modulating cortical activation, delineating an important step for future research refining a protocol being used in a clinical trial to test its efficacy on behaviour, symptoms and clinical outcome.

**Twitter** Janine Bühler @j_buehler_ch, Samantha Weber @SamWeb29, Serafeim Loukas @LoukasSerafeim, Sebastian Walther @WaltherSeb and Selma Aybek @SelmaAybek

**Acknowledgements** The authors thank all patients and healthy controls for their participation.

**Contributors** JB, data collection, data analysis, data interpretation, writing - original draft, writing - review and editing, visualisation, project administration. SW, data collection, data interpretation, advisory input - original draft, SL, data analysis, data interpretation, advisory input - original draft. SW, data interpretation, advisory input - original draft. SA, conceptualisation and study design, data interpretation, writing - original draft, writing - review and editing, project administration. All authors contributed to and approved the final version of the manuscript. SA acts as guarantor.

**Funding** This study was supported by the Swiss National Science Foundation (SNF Grant PPO0P3_210997).

**Competing interests** No, there are no competing interests.
Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the Ethics Committee of Canton Bern, Switzerland (2017-00997). Participants gave their informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error or/and omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Janine Bühler http://orcid.org/0000-0003-0318-8371

REFERENCES